TY - JOUR
T1 - Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets
T2 - The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study
AU - Martineau, P.
AU - Gaw, A.
AU - de Teresa, E.
AU - Farsang, C.
AU - Gensini, G. F.
AU - Leiter, L. A.
AU - Langer, A.
PY - 2007/3
Y1 - 2007/3
N2 - Aims: To investigate whether selecting the starting dose of atorvastatin according to baseline and target (2.6 mmol/L (100 mg/dL) but ≤5.7 mmol/L (220 mg/dL) were assigned a starting dose of atorvastatin (10, 20, 40 or 80 mg/day) based on LDL-C and status of statin use at baseline, with a single uptitration at 6 weeks, if required. There was no washout for ST subjects. At study end, 80% of SF (82%, 82%, 83% and 72% with 10, 20, 40 and 80 mg, respectively) and 59% of ST (60%, 61% and 51% with 20, 40 and 80 mg, respectively) subjects reached LDL-C target. In the ST group, an additional 21-41% reduction in LDL-C was observed over the statin used at baseline. Atorvastatin was well tolerated. Conclusion: This study confirms that individualizing the starting dose of atorvastatin according to baseline and target LDL-C values (i.e. the required LDL-C reduction), allows a large majority of high-risk subjects to achieve target safely, within 12 weeks, with the initial dose or with a single titration.
AB - Aims: To investigate whether selecting the starting dose of atorvastatin according to baseline and target (2.6 mmol/L (100 mg/dL) but ≤5.7 mmol/L (220 mg/dL) were assigned a starting dose of atorvastatin (10, 20, 40 or 80 mg/day) based on LDL-C and status of statin use at baseline, with a single uptitration at 6 weeks, if required. There was no washout for ST subjects. At study end, 80% of SF (82%, 82%, 83% and 72% with 10, 20, 40 and 80 mg, respectively) and 59% of ST (60%, 61% and 51% with 20, 40 and 80 mg, respectively) subjects reached LDL-C target. In the ST group, an additional 21-41% reduction in LDL-C was observed over the statin used at baseline. Atorvastatin was well tolerated. Conclusion: This study confirms that individualizing the starting dose of atorvastatin according to baseline and target LDL-C values (i.e. the required LDL-C reduction), allows a large majority of high-risk subjects to achieve target safely, within 12 weeks, with the initial dose or with a single titration.
KW - Atorvastatin
KW - Coronary heart disease
KW - Diabetes
KW - HMG CoA reductase inhibitors
KW - Low density lipoprotein-cholesterol
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=33846882385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846882385&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2006.03.019
DO - 10.1016/j.atherosclerosis.2006.03.019
M3 - Article
C2 - 16643923
AN - SCOPUS:33846882385
VL - 191
SP - 135
EP - 146
JO - Atherosclerosis
JF - Atherosclerosis
SN - 0021-9150
IS - 1
ER -